Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 70069-853

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 70069-853). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Somerset Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 01)

Chemical structure diagram of Sacubitril and Valsartan, showing the molecular arrangement and stereochemistry of the compound.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 02)

Chemical structure diagram of Sacubitril and Valsartan showing the molecular arrangement and key functional groups, including sodium salts and ring structures, as part of the active ingredient composition.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 03)

A dot plot chart depicting geometric mean ratio and 90% confidence intervals for various coadministered drugs relative to a reference. The drugs listed include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The chart compares two pharmacokinetic parameters, AUC and Cmax, indicated by filled and open circles, respectively, along a horizontal axis labeled "Change relative to reference."*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 04)

Three Kaplan-Meier cumulative incidence curves from the PARADIGM-HF study comparing Sacubitril and Valsartan vs. Enalapril. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations. Figure B shows time to cardiovascular death. Figure C shows time to first heart failure hospitalization. Each graph includes hazard ratios with 95% confidence intervals and patient risk numbers over time.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 05)

A forest plot comparing Sacubitril and Valsartan versus Enalapril across various patient subgroups. The plot displays hazard ratios with 95% confidence intervals for factors such as age, gender, weight, race, region, NYHA class, kidney function, diabetes status, systolic blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, heart failure history, and other clinical variables. The horizontal axis ranges from 0.25 to 4, with markers indicating comparative effect sizes between Sacubitril and Valsartan and Enalapril.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 06)

A line graph titled 'Total Heart Failure Hospitalizations and CV Death in PARAGON-HF,' showing mean number of events per 100 patients over time since randomization in days. Two lines compare outcomes between Valsartan and Sacubitril and Valsartan groups. The x-axis marks time up to 1440 days, and the y-axis represents the mean number of events. Patient numbers at risk at different time points are listed below the x-axis for both groups.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 07)

A forest plot comparing the effect of Sacubitril and Valsartan versus Valsartan across various subgroups, including age, gender, race, geographic regions, diabetic status, LVEF levels, biomarkers, medication use, renal function, and heart failure categories. The plot shows rate ratios with confidence intervals indicating comparative outcomes for each subgroup.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 08)

A line graph depicting hazard ratios with 95% confidence intervals comparing Sacubitril and Valsartan to enalapril in the PARADIGM-HF study and to valsartan in the PARAGON-HF study. The x-axis shows left ventricular ejection fraction at screening (%) and the y-axis shows the hazard ratio.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 09)

Label for Sacubitril and Valsartan Tablets 24 mg/26 mg film-coated tablets by Somerset Therapeutics LLC. The label indicates a 60-tablet count and includes storage instructions, manufacturer details, and dosage information. The product is made in Chile.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 10)

Label for Sacubitril and Valsartan Tablets 24 mg/26 mg film-coated oral tablets. The package contains 180 tablets and is labeled for prescription use only. Manufactured for Somerset Therapeutics, LLC, Somerset, NJ, with the product made in Chile. Storage instructions and dosage notes are included on the label.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 11)

Label for Sacubitril and Valsartan Tablets, 49 mg/51 mg strength, film-coated oral tablets. The package contains 60 tablets. The label includes dosage storage instructions and notes it is manufactured by Somerset Therapeutics, LLC in New Jersey and made in Chile. The NDC is 70069-854-60.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 12)

Label for Sacubitril and Valsartan Tablets, film-coated, 49 mg/51 mg strength. The label indicates a package containing 180 tablets, manufactured for Somerset Therapeutics, LLC, Somerset, NJ. It includes storage instructions and states the product is made in Chile. The NDC number and barcode are also visible.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 13)

Label for Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated oral tablets. The package contains 60 tablets. Manufactured for Somerset Therapeutics, LLC, Somerset, NJ, and made in Chile. The label includes storage instructions and dosage information.*

FDA Label Image

Image (0e853a5e 9eab 4bb6 803d Fd9b97e8b550 14)

Label for Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets, oral use, manufactured for Somerset Therapeutics, LLC. The package contains 180 tablets. Storage instructions specify controlled room temperature between 20°C to 25°C with permitted excursions. The label includes a barcode and the product NDC 70069-855-80.*

FDA Label Image

Image (70f2f2a9 Cfc1 422d B7d1 8666f0d4e02d 113 1)

A figure showing geometric mean ratios and 90% confidence intervals for AUC and Cmax comparing LBQ657 and Valsartan across different population groups. Groups include varying degrees of renal impairment, hepatic impairment, age, sex, and race. The graph plots changes relative to reference values using horizontal bars and markers for both compounds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.